Baltimore David's Form 4 filing
Regulus Therapeutics Inc. (RGLS) · filed Jan 31, 2025
- Accession no.
- 0000950170-25-011850
- Filed
- Jan 31, 2025
- Trade date
- Jan 30, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $20.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baltimore DavidCIK 0001185858 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2025 | Common Stock | PPurchaseAcquired | +19,610 | $1.06F1 | +$20,786.6 | 22,169 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average purchase price for the transaction reported was $1.06, and the range of prices were between $0.97 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.
Referenced by the price of 1 transaction in Table I.